Published online before print May 24, 2007, doi: 10.1161/STROKEAHA.107.483131
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:2127.)
© 2007 American Heart Association, Inc.
Original Contributions |
The Interventional Management of Stroke (IMS) II Study
From the Department of Neurology, The Neuroscience Institute, University of Cincinnati Medical Center, Cincinnati, Ohio.
Correspondence to Joseph P. Broderick, MD, Department of Neurology, 231 Albert Sabin Way, University of Cincinnati Medical Center PO Box 670525, Cincinnati, OH. E-mail joseph.broderick{at}uc.edu
Background and Purpose— The purpose of this study was to further investigate the feasibility and safety of a combined intravenous and intra-arterial approach to recanalization for ischemic stroke.
Methods— Subjects, ages 18 to 80, with a baseline NIHSS 
10 had intravenous recombinant tissue plasminogen activator (rt-PA) started (0.6 mg/kg over 30 minutes) within 3 hours of onset. For subjects with an arterial occlusion at angiography, additional rt-PA was administered via the EKOS micro-infusion catheter or a standard microcatheter at the site of the thrombus up to a total dose of 22 mg over 2 hours of infusion or until thrombolysis.
Results— The 81 subjects had a median baseline NIHSS score of 19. The median time to initiation of intravenous rt-PA was 142 minutes as compared with 108 minutes for placebo and 90 minutes for rt-PA–treated subjects in the NINDS rt-PA Stroke Trial (P<0.0001). The 3-month mortality in IMS II subjects was 16% as compared with the mortality of placebo (24%) and rt-PA–treated subjects (21%) in the NINDS rt-PA Stroke Trial. The rate of symptomatic intracerebral hemorrhage in IMS II subjects (9.9%) was not significantly different than that for rt-PA treated subjects in the NINDS t-PA Stroke Trial (6.6%). IMS II subjects had significantly better outcomes at 3 months than NINDS placebo-treated subjects for all end points (OR 2.7) and better outcomes than NINDS rt-PA–treated subjects as measured by the Barthel Index and Global Test Statistic.
Conclusions— A randomized trial of standard intravenous rt-PA as compared with a combined intravenous and intra-arterial approach is warranted and has begun.
This article has been cited by other articles:
 |
|
 |
|
  O. O. Zaidat, T. Wolfe, S. I. Hussain, J. R. Lynch, R. Gupta, J. Delap, M. T. Torbey, and B.-F. Fitzsimmons Interventional Acute Ischemic Stroke Therapy With Intracranial Self-Expanding Stent Stroke, August 1, 2008; 39(8): 2392 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sugiura, K. Iwaisako, S. Toyota, and H. Takimoto Simultaneous Treatment with Intravenous Recombinant Tissue Plasminogen Activator and Endovascular Therapy for Acute Ischemic Stroke Within 3 Hours of Onset AJNR Am. J. Neuroradiol., June 1, 2008; 29(6): 1061 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nichols, P. Khatri, T. Tomsick, and J. Broderick Advantages of a Combined Approach to Recanalization Therapy Stroke, April 1, 2008; 39(4): e71 - e71. [Full Text] [PDF]
|
|
|
|
|
|
L. Valvassori, A. Ciccone, and R. Sterzi Response to Letter by Nichols et al Stroke, April 1, 2008; 39(4): e72 - e72. [Full Text] [PDF]
|
|
|
|
|
|
T. Tomsick, J. Broderick, J. Carrozella, P. Khatri, M. Hill, Y. Palesch, J. Khoury, and for the Interventional Management of Stroke II Inv Revascularization Results in the Interventional Management of Stroke II Trial AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 582 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Pelz, E. I. Levy, and L. N. Hopkins Advances in Interventional Neuroradiology 2007 Stroke, February 1, 2008; 39(2): 268 - 272. [Full Text] [PDF]
|
|
|
|
|
|
S. King, P. Khatri, J. Carrozella, J. Spilker, J. Broderick, M. Hill, T. Tomsick, and for the IMS & IIMS II Investigators Anterior Cerebral Artery Emboli in Combined Intravenous and Intra-arterial rtPA Treatment of Acute Ischemic Stroke in the IMS I and II Trials AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1890 - 1894. [Abstract] [Full Text] [PDF]
|
|